Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) reported its Q2 2022 financial results and recent progress in clinical studies. Key highlights include:
- Cash reserves of $159.3 million, sufficient to fund operations into H1 2024.
- Net loss reduced to $19.9 million, down from $29.8 million YoY.
- R&D expenses decreased to $16.5 million, primarily due to the wind-down of specific programs.
- Enrollment completed in multiple Phase 1 studies, including ALG-000184 and ALG-125755, with ongoing development of treatments for HBV and NASH.
Management remains optimistic about upcoming clinical trial applications.
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, will report its second quarter financial results on August 4, 2022, after U.S. market close. Founded in 2018, Aligos focuses on developing therapies for viral infections, particularly chronic hepatitis B and coronaviruses, as well as targeted treatments for liver diseases like nonalcoholic steatohepatitis (NASH). With a strategy built on deep expertise in drug development, Aligos aims to advance its pipeline of potentially best-in-class therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) has initiated enrollment for a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) patients in its ongoing Phase 1b study of ALG-000184. CEO Lawrence Blatt emphasized this as a crucial step towards evaluating ALG-000184's potential as a chronic suppressive therapy. Prior results indicated that the drug was well tolerated with promising antiviral activity. Data from this cohort is expected to be shared at a scientific conference in Q4 2022, aiming to assess longer-term dosing effectiveness against elevated viral levels.
Aligos Therapeutics (Nasdaq: ALGS) presented preliminary Phase 1 data from its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) programs at the 2022 European Association for the Study of the Liver Congress. Highlights include significant reductions in HBV DNA and RNA in CHB patients after 28 days of treatment with ALG-000184. Additionally, preliminary results for ALG-055009 in hyperlipidemia patients showed favorable pharmacokinetics and safety. Aligos aims for broader clinical trials and further data releases in Q3 2022.
Aligos Therapeutics announced its participation in the Metropolitan AntiViral Drug Accelerator (MAVDA), a consortium recently awarded a $65 million grant from the NIH and NIAID. MAVDA aims to develop novel antiviral treatments for SARS-CoV-2 and other pandemic viruses. Aligos plans to advance its 3CLpro inhibitor, ALG-097558, into clinical trials, which has shown superior potency against COVID-19 variants compared to existing treatments. The collaboration includes experts from top universities and pharmaceutical companies to expedite drug development.
Aligos Therapeutics (Nasdaq: ALGS) announced that its Chairman and CEO, Lawrence M. Blatt, Ph.D., MBA, will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 PM ET in New York City. The session will cover the company's efforts in developing therapies for viral and liver diseases.
Additionally, Aligos management will participate in investor 1x1 meetings during the conference. A replay of the presentation will be available for 90 days on Aligos' investor website.
Aligos Therapeutics (Nasdaq: ALGS) reported its Q1 2022 financial results, highlighting a net loss of $35.6 million, compared to $27.7 million in Q1 2021. Cash reserves totaled $183.2 million as of March 31, 2022, down from $205.8 million at the end of 2021, but sufficient to fund operations until mid-2024. Despite terminating its STOPS™ and ASO HBV programs due to poor results, Aligos is advancing its pipeline with multiple candidates, including ALG-000184 for HBV and ALG-097558, a coronavirus inhibitor, expected to file for clinical trials in H2 2022.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the presentation of three posters on its chronic hepatitis B (CHB) portfolio at the International Liver Congress 2022 in London from June 22-26, 2022. The posters will cover the safety and efficacy of the class II capsid assembly modulator ALG-000184, the HBV siRNA ALG-125755, and oral PDL1 inhibitors for CHB treatment. These presentations aim to advance Aligos’ diverse CHB portfolio, potentially improving outcomes for patients. The company is committed to developing targeted therapies for viral infections and liver diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced plans to report its first quarter 2022 financial results on May 4, 2022, after U.S. market close. The company focuses on developing innovative therapeutics for viral and liver diseases, including chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Established in 2018, Aligos aims to leverage its expertise in drug development to advance its therapeutic pipeline.
Forward-looking statements in the release highlight potential risks in drug development and market conditions.
Aligos Therapeutics (Nasdaq: ALGS) has announced the selection of ALG-097558 as its leading candidate for development as an antiviral therapeutic against SARS-CoV-2. The compound exhibits potent antiviral activity, being 9 to 20 times more effective than nirmatrelvir against various SARS-CoV-2 variants. Aligos plans to submit a Phase 1 clinical trial application in the second half of 2022 as part of its collaboration with KU Leuven. This development underscores the ongoing need for effective treatments as COVID-19 continues to pose a global health challenge.